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       High-Sensitivity C-reactive protein, Leukocyte and Differential Count in 
Patients with Acute Myocardial Infarction
Introduction
Coronary artery disease remains the leading cause of serious morbidity and mortality 
in adults. Although  standard risk factors account for most of the risk profile in the population, 
they do not explain the picture in its entirety.1  Half of  all  myocardial  infarctions occur in 
persons in whom plasma lipid levels are normal.2  The advancement in the understanding of 
pathophysiology  of  atherosclerotic  vascular  disease  have  thrown  new  insights  regarding 
potential indicators of underlying atherosclerosis and cardiovascular risk.  Due to absence of 
usual clinical symptoms, detection of preclinical atherosclerosis in patients is a challenging 
job. The development of an atherosclerotic plaque involves a complex interaction between the 
endothelium, inflammatory cytokines and various blood elements (Figure 1, 2).  In an effort to 
identify patients at high risk for cardiovascular events, several novel risk markers have been 
proposed for use in screening.
           Inflammation is thought to play a key role in the pathogenesis of coronary artery 
disease.  C-reactive  protein  (CRP),  a  marker  for  inflammation,  is  a  prognostic  marker  for 
stable angina pectoris, unstable angina and non-Q wave myocardial infarction.3,4 
In addition to CRP an elevated white blood cell (WBC) count has been associated with 
the  development  of  coronary  artery  disease  and  long-term  mortality.5 WBC count  is  an 
inexpensive and routine measurement that can be performed on admission to the accident 
and emergency department ; it would be of great benefit to understand if the WBC count has 
any relationship with the risk of developing further complications following acute myocardial 
infarction (AMI). 
Figure 1. Inflammation leads to endothelial dysfunction, plaque progression, plaque erosion and 
rupture, and thrombosis. These events themselves lead to further inflammatory marker/mediator 
release, leading to a dangerous cycle that may cause recurrent ischemic events.
In this prospective study, we aimed to investigate the association between hs CRP and 
white  cell  count,  obtained on admission,  and  the  development  of  subsequent  in  hospital 
adverse  events  in  patients  with  an  acute  ST  segment  elevation  myocardial  infarction. 
Previous studies did not contain information regarding the WBC differential  count and it's 
correlation with the hs CRP level and short-term prognosis, which might have contributed 
important additional information.
Aim & Objectives
Aim:
To assess the association of high sensitivity C-reactive protein and white cell  count to in-
hospital complications of STEMI.
Objectives:
1. To evaluate the prognostic value of CRP measured as high sensitivity               C-
reactive  protein  assay  (hs-CRP)  in  patients  with  ST  segment  elevation  myocardial 
infarction.    
2.  To investigate the relationship between total  and differential  WBC count obtained on 
admission with parameters such as LV systolic function and the development of post MI 
complications during the hospital course.
Review of Literature
Inflammation plays a crucial role in the biology of atherosclerosis. In recent years, it 
has been recognized that atherogensis represents an active    inflammatory process rather 
than a simply passive injury with infiltration of lipids. Inflammation characterizes all phases of 
atherothrombosis and provides a critical pathophysiological link between plaque formation, 
acute rupture, leading to occlusion and myocardial infarction. Formation of fatty streak, the 
earliest phase of atherogenesis, involves recruitment of leukocytes due to the expression of 
adhesion molecules on endothelial cells; in turn triggered by inflammatory cytokines such as 
interleukin-1 and tumor necrosis factor-alpha. Subsequent migration of inflammatory cells into 
the subendothelial space requires chemotaxis controlled by chemokines, induced by primary 
cytokines. Mononuclear cells within initial infiltrate as well as intrinsic vascular cells release 
growth  factors  that  stimulate  proliferation  of  smooth  muscle  cells  and  lead  to  plaque 
progression.  Thrombotic  complications  of  plaque  s  often  involve  physical  disruption 
associated  with  both  local  and  systemic  inflammation.  Several  mediators  or  markers  of 
inflammation and various sources   have been described (Figure 2).  Table 1 shows the assay 
of inflammatory markers, which have potential for clinical use.
Figure 2.  There are several inflammatory mediators from various sources that participate in arterial 
inflammation. Numerous different cell types participate in the process of arterial inflammation. In the 
context of arterial inflammation, most of these mediators are viewed as deleterious.  However, the 
ones in italics are believed to be beneficial CRP, C-reactive protein: ICAM, intercellular cell adhesion 
molecule;IL,  interleukin;  LpPLA2 lipoprotein-associated  phospholipase  A2;  MIC-1,  macrophage 
inhibitory cytokine-1: MMp1 matrix metalloprolelnase; PDGF, platelet derived growth factor, RANTES, 
regulated on activation  normally  T-cell  express  and  secreted;  SMCs,  smooth  muscle  cells;  TGF, 
transforming growth factors TNF, turnor necrosls factor; VCAM, vascular cell adhesion molecule.
Table 1. Assays of inflammatory Markers for Potential Clincal Use6
Analyte Stability Assay 
Availability
World Health 
Orgainsation 
Standards Available
Soluble adhesion 
molecules 
(e.g.,E-Selectin, 
P-Selectin, Intracellular 
adhesion molecule-1)
Unstable (Unless 
frozen)
Limited No
Cytokines 
(e.g., interleukin-1b, -6, 
-8, and 10 and tumor 
necrosis factor -a )
Unstable (Unless 
frozen)
Few Yes
Acute-phase reactants
Fibrinogen
 SAA
             hs-CRP
 WBC count
Unstable (Unless 
frozen)
Stable
Stable
Stable
Many
One
Many
Many
Yes
Yes
Yes
Yes
High-Sensitivity C - reactive protein:
The  primary  proinflammatory  cytokines  result  in  messenger  cytokines  such  as 
interleukin -6,  which travel  from local  site of  inflammation to the liver,  where it  triggers a 
change in  the program of  protein  synthesis,  characteristic  of  acute phase response.  The 
acute  phase  reactant,  C-reactive  protein  (CRP),  a  simple  down  stream  marker  of 
inflammation has emerged as a major cardiovascular risk factor and as the “golden marker” 
for inflammation.7 CRP is a circulating member of pentraxin family that plays a major role in 
the human innate immune response. Although it is primarily derived from the liver, recent data 
indicate that cells within human coronary arteries, particularly from the atherosclerotic intima 
can elaborate CRP. Recently improved high sensitive and standardized quantitative assays in 
serum have allowed a re-evaluation of its potential as a diagnostic laboratory test. hs-CRP 
level has been proven to be a marker for risk stratification in primary cardiovascular disease 
prevention.  The predictive values of  hs-CRP are significantly higher than other traditional 
biochemical  cardiovascular  risk  markers  like  total  cholesterol,  HDL-cholesterol,  LDL-
cholesterol, lipoprotein (a), homocysteine, apoliprotein A1 and B. 
C reactive protein Structure:
Tillet & Fransis first described C-reactive protein in 1930. They concluded that sera of 
patients  suffering  from  acute  infection,  precipitated  with  a  non-protein  pneumococcus 
extracts, called C-polysaccharide in the presence of calcium ions. The protein that caused 
this reaction was called C-reactive protein (CRP).8  It belongs to pentraxin family of proteins 
(PTX-1); ability to form pentameric structures formed by non-covalent interactions, and hence 
the name.(Figure 3a).  CRP is a mature chain 206 aminoacid, non-glycosylated, ubiquitous 
protein  found in both vertebrates and invertebrates.  Each protomer has the characteristic 
“lectin fold”, composed of a two-layered sheet with a flattened jellyroll topology (Figure 3b). 
The ligand-binding site composed of loops with two calcium ions is located on the concave 
side. 
Figure - 3a    
Negatively stained electron micrograph showing the typical pentameric disc-like structure of hs-CRP 
8
Figure 3b
Ribbon diagram of the crystal structure, showing the lectin fold and the two calcium atoms (spheres) 
in the ligand-binding site of each protomer of hs-CRP 8. 
CRP is composed of 5 identical (pentraxin), 23KD subunits. It is produced in the liver 
(Chromosome 1q21-23). It is detectable on the surface of about 4% of normal peripheral 
blood lymphocytes. It has a half-life of 18 to 20 hours.  The median concentration of CRP in 
healthy young adults is 0.8 mg/L, the 90th centile is 3.0 mg/L and the 99th centile is 10mg/L. 
CRP value tends to slightly increase with age.  It is a stable compound and shows little 
variation in repeated measurements.  There is no significant diurnal variation or difference 
between fasting and non-fasting values.
Why C reactive protein is a strong predictive biomarker?
Choosing CRP as a predominant biomarker of cardiovascular events, is due to some 
of its potential advantages over other biomarkers.9
CRP has: 
• Long half-life (18 to 20 hours) 
• Lack of age and sex dependence 
• Lack of diurnal variation 
• It is also a factor of proatherogenesis 
• Long-term stability during storage (no special collection procedure) 
CRP is a more sensitive and reliable indicator of inflammatory process than the ESR and 
the leukocyte count. The  serum  CRP concentrations increase faster than that of the ESR 
and when the condition  subsides, CRP falls very quickly, reaching normal levels, several 
days before the ESR normalizes. Rises in CRP are only one part of a number of intricate 
changes in serum proteins and enzymes, but it can be a parameter that can be  measured 
early.
Functions And Mechanisms Relating C-Reactive Protein (CRP) To The Development 
And Progression Of Atherothrombosis: 
CRP binds to a variety of autologous and extrinsic ligands.  Autologous ligands include 
plasma lipoproteins, damaged cell membranes, phospholipids etc. Extrinsic ligands are 
mainly constituents of microorganisms such as capsular and somatic components of bacteria, 
fungi and parasites. After binding, CRP activates the classical complement pathway and the 
terminal membrane attack complex. Activation of complement causes opsonization and 
enhances phagocytosis of the various ligands. Thus, CRP is thought to contribute to host 
defense against infection and may also protect against autoimmunity.
 The function of CRP is related to its role in the innate immune system. Similar to IgG, it 
activates complement, binds to Fc–receptors and acts as an opsonin for various pathogens.11 
Interaction of CRP with Fc–receptors leads to the generation of proinflammatory cytokines 
that enhance inflammatory response. 
Unlike IgG, which specifically recognizes distinct antigenic epitopes, CRP recognizes 
altered self and foreign molecules based on pattern recognition. Thus, CRP is thought to act 
as a surveillance molecule for altered self antigens and certain pathogens. This recognition 
provides an early defense and leads to a proinflammatory signal and activation of the humoral 
adaptive immune system. Thus, a number of functions have been ascribed to CRP, including 
initiation of  opsonization and phagocytosis and activation of  complement,  neutrophils and 
monocyte-macrophages. Collectively these properties imply an important role for CRP in the 
recognition of microbial organisms and as an immunomodulator in the host defense. CRP 
may also be important  in  the recognition of  necrotic  tissues.  It  binds to  phospholipids of 
damaged cells with subsequent limited activation of the complement system and enhanced 
uptake of these cells by macrophages.
CRP binds to apoptotic cells, protects cells from assembly of the terminal complement 
components and sustains an anti-inflammatory innate immune response. CRP binds with high 
affinity to chromatin. It has been proposed  that one of its major physiologic functions is to act 
as a scavenger for chromatin released by dead cells during the acute inflammatory process. 
Thus, CRP has both recognition and an effectors function. Determination of CRP is of a great 
value in diagnosis, treatment and monitoring of inflammatory conditions. CRP may influence 
directly vascular vulnerability through several mechanisms (Figure 4,5), including enhanced 
expression of local adhesion molecules, increased expression of endothelial PAI-1, reduced 
endothelial nitric oxide bioactivity, altered LDL uptake by macrophages, and co-localization 
with complement within atherosclerotic lesions. 
Figure 4. Mechanisms relating C-reactive protein (CRP) to the development and progression of 
atherothrombosis.12
CRP has proatherogenic properties 13,14
• It leads to the activation of: 
Endothelial cell adhesion molecules (ECAMs) 
Intercellular adhesion molecule-1 (ICAM-1) 
Vascular cell adhesion molecule-1 (VCAM-1) 
Selectin-E&P
Monocyte Chemo attractant protein-1 (MCP-1) 
• Recruits monocytes into the arterial wall 
• Blunts endothelial activity 
• Stabilizes plasminogen activator inhibitor-1(PAI-1) mRNA 
• Decreases endothelial nitric oxide synthase expression 
• Activates nuclear factor-kappa
 
Figure  5. CRP  colocalizes  with  LDL-C  and,  following  its  specific  receptor-directed  uptake  into 
monocytes,  1)  stimulates  tissue  factor  expression,  2)  complement  activation,  and  3)  adhesion 
molecule up-regulation.15
CRP has been shown to be deposited in human atherosclerotic plaques, especially the 
complex ones,  and the locally concentrated CRP may be present in sufficient amount to 
promote the development of the atherosclerosis.14 CRP activates macrophages to express 
cytokines and tissue factor (TF) and enhances the uptake of LDL.14 CRP also amplifies the 
proinflammatory effects of several other inflammatory mediators, including endotoxin.15 A key 
feature in the inflammatory hypothesis of atherosclerosis is the recognition of circulating 
immune cells and recruiting to the inflamed vessel by interacting with adhesion molecules and 
cytokines.
Role of CRP and Endothelial dysfunction: 
Recently, it has been suggested that CRP also affects nitric oxide (NO) pathways16, 17 
relating to the association between endothelial dysfunction and atherosclerosis. CRP is an 
important regulator of tone of both resistance and conduit vessels in vivo.18 CRP leads to the 
induction of IL-6 (Inter leukin-6) and ET1 (Endothelin-1), there by decreasing the expression 
and bioavailability of  e-NOS in endothelium,16,17,18  but human and rat  experiments showed 
functionally active highly purified human CRP directly increased rather than decreasing nitric 
oxide bioavailability in blood vessels in vitro, in contrast to earlier reports.17 So CRP can have 
specific, direct effects on vascular function via nitric oxide pathways.18
Evolution  of  the  atherosclerosotic  plaque  and  role  of  hs  CRP: The  cytokines  thus 
induced  increase  expression  of  adhesion  molecules  for  leukocytes  that  cause  their 
attachment and chemoattractant molecules that direct their migration into the intima. Blood 
monocytes upon entering the artery wall in response to chemoattractant cytokines such as 
monocyte chemoattractant protein 1 (MCP-1), encounter stimuli such as macrophage colony 
stimulating  factor  (M-CSF)  that  can  augment  their  expression  of  scavenger  receptors. 
Scavenger receptors mediate the uptake of modified lipoprotein particles and promote the 
development of foam cells.
Figure  6. Schematic of the evolution of the atherosclerosotic plaque 19
Macrophage foam cells are a source of mediators such as further cytokines and effector 
molecules such as hypochlorous acid, superoxide anion (O2-), and matrix metalloproteinases. 
Smooth muscle cells migrate into the intima from the media and smooth muscle cells in the 
intima divide. Smooth muscle cells divide and elaborate extracellular matrix, promoting 
extracellular matrix accumulation in the growing atherosclerotic plaque. In this manner, the 
fatty streak can evolve into a fibrofatty lesion. In later stages, calcification can occur and 
fibrosis continues, sometimes accompanied by smooth muscle cell death (including 
programmed cell death) yielding a relatively acelluar fibrous capsule surrounding a lipid-rich 
core that may also contain dying or dead cells and their detritus (see figure 6). 19
    Despite the importance of CRP in the management of acute coronary syndromes, very 
few studies have addressed the relation between lesion morphology and CRP. Sano et al 
suggested that the presence of ruptured plaque is only related to elevated CRP in patients 
with  AMI  less  than  six  hours.  As  mentioned  previously  CRP is  mainly  synthesized  and 
secreted by hepatocytes 6 hours after an acute stimulus and shows rapid turnover (with a 
half-life of 19 hours). Myocardial necrosis also promotes the synthesis of CRP. 20 Sano et al 
included patients in his study with AMI treated within 6 hours of the onset of symptoms. There 
was no elevation in CK-MB and Troponin T at admission, which suggests that elevated CRP 
levels may reflect properties of the coronary lesions just before rupture but are unlikely to 
reflect  myocardial  necrosis.  Plaque rupture occurs most frequently at  the point  where the 
fibrous cap is thinnest and most heavily infiltrated by macrophage foam cells. These rupture-
related  macrophages are  activated,  indicating  ongoing  inflammation  at  the  site  of  plaque 
disruption. Macrophages are capable of degrading the extracellular matrix by phagocytosis or 
by secreting proteolytic enzymes such as plasminogen activators and the family of matrix 
metalloproteinases,  that  may  weaken  the  fibrous  cap,  predisposing   it  to  rupture  and 
suggested  that  elevated  CRP  may  reflect  the  activity  of  activated  macrophages  in  the 
atheroscerotic plaque also plays an important key role in plaque disruption.20  Ridker et al 
studied immunohistochemical staining for CRP, in patients who had sudden death associated 
with severe coronary artery disease and reported that CRP may correlate with the number of 
thin-capped atheromas that can be considered vulnerable plaques and  also suggested that 
CRP is elevated in the setting of “active” angina and that elevated CRP may be a predictor of 
a future risk of the onset of AM.21 Ridker et al results may help to explain why elevated CRP 
may  predict  the  future  onset  of  AMI.  It  has  also  been  reported  that  coronary  calcium 
deposition may be a feature of atherosclerosis and plaque rupture and may predict future 
coronary events.9 This has led to speculation that coronary calcium deposition may be related 
to CRP.  However, the evidence for a relation between coronary calcium and CRP on electron 
beam computerized tomography studies is controversial.  Both coronary calcium and CRP 
independently contribute risk stratification towards the incidence of cardiovascular  events. 
Neither superficial nor deep calcium deposition, as identified by IVUS, is associated with CRP 
elevation  and  suspect  that  elevated  CRP  and  calcium  deposition  reflect  a  different 
pathological status in patients with AMI.20 Normal CRP group, 44% were                  non–
rupture type lesions. Pathological evaluation has shown that AMI caused not only by plaque 
rupture but also by plaque erosion, which is a major substrate for coronary thrombosis in AMI 
and eroded proteoglycan-rich and smooth muscle               cell–rich plaques lack a superficial 
lipid core, are less likely to see plaque rupture, and have fewer foci containing macrophages. 
Non-ruptured  lesions  are  thought  to  cause  a  less  inflammatory response  compared  with 
ruptured lesions. 20
hs-CRP and  acute myocardial infarction :
MI is invariably associated with a major CRP response. The peak value of CRP occurs 
about 50 hours after the onset of pain in MI. In patients who recover uneventfully, the CRP 
falls rapidly towards normal in the usual exponential fashion, reach baseline over 3-5 days. 
However, complications such as persistent cardiac dysfunction, further infarction, aneurysm 
formation,  intercurrent  infection,  thromboembolism  are  associated  with  either  persistently 
raised CRP levels  or  secondary increase after  the initial  decrease.   European Concerted 
Action on Thrombolysis and Disabilities study showed that elevation of CRP levels by 20% or 
more was found in survivors of MI and it increases further if other sites, such as peripheral 
vasculature are also involved.25 Hence CRP may serve to represent the inflammatory burden. 
Monitoring Trend and Determinants in Cardiovascular diseases Trial45  showed that highest 
CRP level has 2.6 times higher risk of MI.  Bazzino et al23   reported that post infarction angina 
occurred in only 14% of patients with a normal CRP level, by comparison, 64% of patients 
admitted with high CRP levels had evidence of post infarction angina, nearly 42% required 
revascularization, and 21% had recurrent MI.  Walter et al 24 reported that in patients with MI, 
increased  CRP  concentration  is  associated  with  the  presence  of  complex  angiographic 
lesions and the need for revascularization. 
It  was demonstrated that in the patient group with unstable angina or non-Q wave MI, 
abnormal CRP levels on admission and elevated levels of troponin I are important for the 
incidence of major cardiac complication within six months.24 
Evidence that hs-CRP is a predictor of adverse events in the stable phase after MI is less consistent 
than evidence of its prognostic ability in primary prevention or in acute coronary settings. In the Cholesterol and 
Recurrent Events (CARE) secondary prevention trial of pravastatin, patients with elevated hs-CRP levels at 3 to 
20 months after the index MI were at higher risk of recurrent events during the 5-year follow-up period. 
Data from Physician Health Study (PHS),) showed that CRP is a stronger predictor of cardiovascular 
events  than  LDL.  Paul  Ridker  et  al27  showed  that  when  risk  estimates  with  95% confidence  intervals  are 
compared for the each marker,hs-CRP and hs-CRP + total cholesterol: HDL-C ratio had the highest prediction of 
relative risk of future cardiovascular events. Because it disappears rapidly when inflammation subsides, CRP 
detection signifies the presence of a current inflammatory process. Further, by serial measurements important 
information can be obtained on the resolution or continuation of the inflammatory process. CRP has been shown 
in multiple randomized controlled trials that, it can predict incidence of MI, stroke, peripheral arterial disease, 
sudden cardiac death, recurrent ischemia and death in chronic stable angina, acute coronary syndromes and 
cardiovascular events in those undergoing PCI.
CRP value as a predictor of risk has recently been questioned.  Danesh et al reported 
that CRP concentration was a relatively moderate predictor of the risk of CAD and added only 
marginally to the predictive value of established risk factors for CAD. They reported that, after 
adjustment for baseline values for established risk factors, the odds ratio for the CAD was 
1.45  (95%CI  1.25  to  1.68)  in  a  comparison  of  participants  in  the  group  with  respect  to 
baseline CRP.28   
hs-CRP   and  first coronary events :
              Ten prospective studies, 6 in USA and 4 in Europe, have consistently shown that hs-
CRP is  a powerful  predictor of  future first  coronary event  in  apparently healthy men and 
women.  Multiple  Risk  Factors  Intervention  Trial  (MRFIT)  demonstrated  a  direct  positive 
association between hs-CRP and CAD mortality in men followed over a 17-year period (RR = 
2.8;  95% CI,  1.4 – 5.4).  This relationship,  however,  was evident only among smokers.  A 
similar  association  between  hs-CRP  and  future  coronary  events  was  noted  in  the 
Cardiovascular Health Study and Rural Health Promotion Project, which included men and 
women over 65 years of age with subclinical cardiovascular disease. The Physician’s Health 
Study (PHS), demonstrated similar positive association between hs-CRP and future coronary 
events in apparently healthy men. Unlike the observation in MRFIT, however, this association 
was evident in both smokers and nonsmokers. This study showed that those in the highest 
quartile of hs-CRP had a 2-fold higher risk of future stroke (RR = 1.9; 95%CI, 1.1 – 3.3), 3-
fold higher risk of future MI (RR= 2.9; 95% CI, 1.8 – 4.6), and 4-fold higher risk of future 
peripheral vascular disease (PVD); (RR = 4.1; 95% CI, 1.2 – 6.0). The relative risks were 
stable over a long period of time (6 years) and independent of other CAD risk factors. The 
European  MONICA  (Monitoring  Trends  and  Determinants  in  Cardiovascular  disease) 
Augsburg study showed that an increase of one standard deviation in the log-transformed 
value of hs-CRP was associated with a 50% increase in coronary risk and that subjects with 
hs-CRP concentrations in the highest quintile had a 2.6-fold higher risk of developing future 
coronary events. Helsinki Heart Study confirmed these observations and demonstrated that 
those in the highest quartile of hs-CRP had a more than 3-fold higher risk of future MI or 
cardiac death (RR = 3.56; 95%CI, 1.93 – 6.57). The Women’s Health Study (WHS) showed 
that hs-CRP is a strong predictor of future events in women (RR = 4.4; 95% CI, 2.2 – 8.9).  In 
stratified analysis, hs-CRP continued to be a strong predictor of future cardiovascular events 
even among subgroups of women with no history of hyperlipidemia, hypertension, smoking, 
diabetes  or  family  history  of  CAD. 21 The  hs-CRP  concentrations  seen  in  these 
postmenopausal  women were  some what  higher  than  those  reported  previously  in  men. 
Although no difference in hs-CRP values was noted between premenopausal women and 
age-matched males,  recent  reports  showed that  hormone  replacement  therapy (estrogen 
alone  or  estrogen  and  progestin)  is  associated  with  increased  hs-CRP  concentrations.31 
These findings suggest that the increased hs-CRP seen in the WHS subjects may reflect the 
influence of hormone replacement therapy rather than the effect of gender.
hs CRP  after percutaneous coronary intervention   : 
Elevated CRP levels may also represent a biomarker for patients who are susceptible 
to  re-occlusion.  In  patients  with  stable  CAD,  who  underwent  stent  implantation  following 
angioplasty, CRP levels increased over 96 hours in those with restenosis. In patients without 
restenosis, CRP levels peaked at 48 hours and then declined. In patients who have stable 
angina and disease in one vessel and have stent placement, normal CRP levels before the 
procedure  or  normalization  of  CRP  levels  within  72  hours  after  coronary  artery  stent 
placement identifies a large subset of patients who are unlikely to have cardiovascular events 
during the twelve-month follow-up.29 
Zebrack et al 30 followed 2554 patients undergoing coronary angiography for evaluation 
of  symptoms  of  stable  (65%)  or  unstable  (35%)  angina.  In  this  cohort,  72% of  patients 
received medical therapy only, 9% received angioplasty, and 19% received bypass surgery. 
After 2 years of follow-up, hs-CRP levels of 10 mg/L or higher (vs <10 mg/L) were predictive 
of  death or future MI in patients with CAD (Relative risk [RR],  2.1;  95% CI,  1.5-3.1) and 
patients without CAD (RR, 2.3; 95% CI, 0.9-5.5). Moreover, CRP retained predictive value at 
each quintile of CAD severity. Indeed, the absolute risk of death or MI among patients with 
the lowest CAD scores(i.e., those with normal angiograms) and the highest hs-CRP levels 
(11.1%) exceeded the risk for patients with the highest CAD scores and the lowest hs-CRP 
levels (8.4%), despite a higher prevalence of traditional coronary risk factors in the group with 
more extensive CAD. A similar pattern of results was observed for the outcome of MI alone.30
The precise  source  of  CRP elevations  remains  unclear.  In  a  small  study,  hs-CRP 
levels did not change after PTCA in patients with stable or unstable angina and normal pre 
procedural  CRP levels  but  did  increase after  PTCA in patients  with  unstable  angina and 
elevated hs-CRP levels at baseline. These data suggest that plaque rupture per se may not 
be  the  source  of  elevated  hs-CRP levels  among  persons  with  unstable  angina;  instead, 
elevated hs-CRP in this setting may be a marker of hyper responsiveness of the inflammatory 
system to even small stimuli underlying inflammation i.e, those with elevated levels of hs-
CRP. Few data are available regarding hs-CRP in the setting of coated stents. However, 
because sirolimus and similar coatings present an antiproliferative, anti-inflammatory surface 
interface with the endothelium, these stents likely will decrease event rates the most among 
individuals  with  the  highest  levels  of  CRP.  It  has  been  demonstrated  that  there  was  an 
increase in procoagulant activity in patients who underwent successful primary angioplasty for 
AMI and that this increase in procoagulant activity was associated with an increase in Mac-1 
expression  on  circulating  leukocytes.  Finally,  the  adherence  of  activated  platelets  to 
polymorphonuclear leukocytes via Mac-1 may also play a role in thrombus formation. Patients 
with an elevated WBC count had reduced patency and greater thrombus burden and had a 
poorer  downstream microvascular  perfusion  as  assessed with  TIMI  perfusion grade.  This 
impaired  myocardial  perfusion  reflects  leukocyte-mediated  endothelial  dysfunction  and 
microvascular plugging, as described in animal models. 
Leukocyte in cardiovascular disease
Table 2. Mechanisms by which leukocytosis may predispose to 
ischemic vascular events     
Prothrombotic effects
1) Synergism with platelets in providing a catalytic surface for thrombin generation, 
including receptors for  fibrinogen and proteolytic activity that can activate 
coagulation factor intermediates and platelets,
2) Platelet–leukocyte aggregates and transcellular metabolism
3) Prothrombotic alteration of fibrinogen by post-translational, myeloperoxidase-
enhanced nitrating oxidants
Vascular effects
1) Rheologic compromise of microvasculature by adhesion, aggregation, platelet 
recruitment, and   obstruction
2) Release of proinflammatory and vasculotoxic factors, reactive oxygen species, 
proteases, eicosanoids, growth factors, interleukins, and  myeloperoxidase
Acceleration of atherosclerosis
1) Monocyte infiltration
2) Leukocyte-dependent oxidation of low-density lipoprotein and HDL
3 ) Platelet–leukocyte aggregates
4) Contribution to intimal hyperplasia after vascular injury
The leukocyte count is a marker of inflammation that is widely available in clinical 
practice. Correlation of the leukocyte count with CAD and investigations into the utility 
of the leukocyte count as a risk factor and prognostic indicator in patients with CAD are 
consistent  with the  current  concept  that  atherosclerosis  is  an  active  inflammatory 
process rather  than simply passive injury with infiltration of  lipids. According to  this 
concept, monocytes are recruited from the peripheral blood into the vessel wall after 
endothelial injury.  The  recruited  monocytes  differentiate  into  macrophages that 
phagocytose lipids and secrete metalloproteinase enzymes.
Proteolytic and oxidative vascular damage: Leukocytes may influence the development of 
CAD through their ability  to  cause proteolytic  and oxidative  damage to  coronary arteries. 
Stimulated neutrophils are known to: 1) secrete proteolytic neutral proteases that promote the 
detachment  of  endothelial cells  from  vessel  walls  and  the  adherence  of  platelets  to 
subendothelial collagen and fibronectin; 2) release large amounts of the chemotactic agent 
leukotriene  B4 in  patients  with  stable  angina; 3)  secrete  large  amounts  of  inflammatory 
mediators and 4) release superoxide anions in hyperlipidemic patients.  Some researchers 
have observed increased neutrophil aggregation and oxidase activity in the coronary sinuses 
of patients with angiographically documented CAD.39  Oxygen-free radicals play an important 
role in the atherosclerotic process, but their destructive effects can be prevented, at least in 
theory,  by  antioxidant  enzymes  such as  superoxide  dismutase  and  catalase  proteolytic 
enzymes are another likely source of arterial damage. 
Vessel plugging:   Leukocytes may influence the development of CAD through their ability to affect blood flow 
through the cardiac microvasculature and because they are stiffer and larger  than either  red blood cells or 
platelets, leukocytes may obstruct small nutrient vessels.  In patients with acute MI, the leukocytosis that follows 
necrotic injury usually although not always renders leukocytes less deformable and less able to pass through the 
microvasculature, thus aggravating ischemia, extending the infarct area, and leading to further complications. 
Adhesion molecules on leukocytes become up regulated or down regulated in atherosclerosis, hence increasing 
chemotaxis of monocytes beneath the endothelium in early stages of atherosclerosis. 
Abnormal leukocyte aggregation:   Abnormal leukocyte aggregation may play a role in CAD similar to platelets 
and granulocytes aggregate when stimulated. In patients with peripheral vascular disease, increased platelet 
number and activity, neutrophil count, and acute-phase reactant protein levels correlate with increased plasma, 
serum, and blood viscosity and mononuclear leukocytes become less filterable during periods of ischemic pain. 
Abnormal leukocyte aggregation and high leukocyte count may even be seen as a manifestation of hematologic 
stress syndrome.40 
Leukocytes and infarct expansion :  During reperfusion of ischemic myocardium, neutrophils and platelets can 
plug capillaries in the coronary microcirculation, resulting in the no-reflow phenomenon, ventricular arrhythmia, 
loss of coronary vascular reserve, infarct extension, and even organ dysfunction. The vascular obstruction may 
be partly due to the binding of  neutrophils to ischemic endothelium integrins such as CD18B and adhesion 
molecules such as intercellular adhesion molecule (ICAM)-1. Support for this idea comes from the observation 
that treatment with CD18 antibodies can reduce infarct size as well as the observation that a deficiency in either 
CD18 or ICAM-1 can markedly reduce neutrophil  accumulation and myocardial necrosis after MI-reperfusion 
injury.41  The mechanism of  action underlying neutrophil-induced infarct expansion remains unclear.  Perhaps 
reperfusion further inflames areas that are already ischemic, resulting in the accumulation of neutrophils (see 
figure 7) that then worsen the existing myocardial damage by unleashing more destructive oxygen-derived free 
radicals, proteases,  and  leukotrienes.  This  view  is  borne  out  by  experimental studies  showing  the 
cardioprotective  effects  of  neutrophil  inhibition and the interference of  monoclonal  antibodies in  interactions 
between leukocytes and endothelium.
Figure 7. Dense   polymorphonuclear   leukocytic  infiltrate  in an area of acute myocardial infarction 
of 3 to 4 days duration
Leukocytes and hypercoagulability: Leukocyte count correlates positively with coagulation factors, including 
fibrinogen and factors VII  and VIII.69  It  is  also known that the systemic inflammatory response that  usually 
follows successful reperfusion involves the expression of cytokines (interleukin (IL)-1-beta, IL-8, and IL-6) and 
adhesion molecules [macrophage adhesion molecule (MAC)-1] on circulating monocytes, which in turn leads to 
increased monocyte procoagulant activity.70 Both IL-6 and -8 exert their procoagulant effects in a time- and dose-
dependent  fashion and at  concentrations found in  the peripheral  blood of  patients  with  acute  MI.  MAC-1-a 
beta2integrin that mediates the adhesion of leukocytes to vessel walls, catalyzes the conversion of factor X to 
factor Xa and binds fibrinogen mediating the adherence of activated platelets to neutrophils and any thrombosis 
that may follow. 
Leukocytes and reperfusion:   The leukocyte count  immediately after a coronary event  may influence the 
chances of successful reperfusion. One study of patients undergoing thrombolytic therapy after an acute MI42 
found that those with higher non-neutrophil count at presentation achieved successful reperfusion (i.e., TIMI flow 
grade 3) more often. This observation may be due to the fact that a longer time from symptom onset to treatment 
was associated with a higher neutrophil count and a lower non-neutrophil count, and this delay in treatment has 
affected the response to reperfusion. In general, an increased leukocyte count immediately after acute MI has 
been associated with poorer myocardial reperfusion, higher  mortality, increased risk of new-onset CHF or shock, 
thromboresistance, and  greater  thrombus  burden.43  The  increased  thromboresistance, may  be  due  to  the 
enhanced generation of thrombin at sites of vascular injury by circulating monocytes and neutrophils that have 
been recruited to such sites. The enhanced thrombin production is mediated by interactions between P-selectin 
glycoprotein ligand-l  expressed  by  leukocytes  and  P-selectin  expressed  by activated  platelets  and  by  the 
monocytes themselves. These interactions make the membrane surface available for the assembly and function 
of coagulation complexes involved in tissue factor-initiated thrombin production. 
Leukocytes and electrical instability :   Leukocyte count may affect the electrical stability of 
the heart.  A study by Maisel  et  al  has shown that a high leukocyte count is  a significant 
predictor of ventricular fibrillation in patients who have suffered an acute MI.
White cell count and Lesion Morphology   :    
         In addition to neutrophils mast cells that secrete or induce degradative proteases begin 
to accumulate in the plaque. Over time, the recruitment and accumulation of inflammatory 
cells  increase  the  lipid  and inflammatory cell content  of  the  plaque  and cause  extensive 
neovascularization of  involved  adventitia  and  intima.  The  atherosclerotic plaque  becomes 
more  vulnerable  to  rupture,  leading  to  cardiovascular events.  When  plaque  rupture  does 
occur,  it  is  usually  followed immediately  by  mural  or  occlusive  coronary  thrombosis  and 
dynamic vasoconstriction  on  exposed  intimal  tissue  in  or  near  areas of  luminal 
inflammation.32,33 Plaque rupture occurs most frequently at the point where the fibrous cap is 
thinnest  and  most  heavily  infiltrated  by  macrophage  foam  cells.  These  rupture-related 
macrophages are activated, indicating ongoing inflammation at the site of plaque disruption. 
Macrophages  are  capable  of  degrading  the  extracellular  matrix  by  phagocytosis  or  by 
secreting  proteolytic  enzymes  such  as  plasminogen  activators  and  the  family  of  matrix 
metalloproteinases that may weaken the fibrous cap, predisposing it to rupture. Burkers etal 
in a  pathological study reported that eroded proteoglycan-rich and smooth muscle cell–rich 
plaques lack a superficial lipid core, are less likely to  plaque rupture, and have fewer foci 
containing macrophages.20 Non ruptured lesions are thought to cause a less inflammatory 
response compared with ruptured lesions. 
WBC  and  percutaneous  coronary  intervention Thus,  regardless  of  the  mechanism 
underlying  the association  between  leukocytosis  and  mortality  after  acute  myocardial 
infarction,  it  appears  that  reperfusion  and  early  revascularization strategies  mitigate  or 
eliminate the association between WBC count and mortality during the first 6 months after a 
myocardial infarction. Bhatt etal.67 data suggest that patients who are not eligible for, or who 
do not receive, reperfusion or revascularization therapy may be a more appropriate group in 
which to test the effect of interventions to lower the WBC count.  Many epidemiologic and 
clinical  studies  have  shown  leukocytosis  to be  an  independent  predictor  of  future 
cardiovascular events, both in healthy individuals free of CAD at baseline and in patients with 
stable angina, unstable angina, or a history of  myocardial infarction. This relationship has 
been observed in prospective and retrospective cohort  studies,  as well  as in case-control 
studies. It  is  strong,  consistent,  temporal,  dose-dependent, and biologically plausible.  The 
relationship persists after adjustment for multiple CAD risk factors, including smoking.
It  has  been  demonstrated  that  there  was  an  increase  in  procoagulant  activity  in 
patients  who underwent  successful  primary angioplasty for  AMI  and that  this  increase in 
procoagulant  activity was associated with  an increase in  Mac-1 expression on circulating 
leukocytes. Finally, the adherence of activated platelets to polymorphonuclear leukocytes via 
Mac-1 may also play a role in thrombus formation. Patients with an elevated WBC count had 
reduced  patency  and  greater  thrombus  burden  and  also  had  a  poorer  downstream 
microvascular  perfusion  as  assessed  with  TIMI  perfusion  grade.  One  option  is  that  this 
impaired  myocardial  perfusion  reflects  leukocyte-mediated  endothelial  dysfunction  and 
microvascular  plugging,  as  described  in  animal  models  of  ischemia  reperfusion.  When 
comparative analyses were conducted within a single study, the association between mortality 
after myocardial infarction and leukocyte count was less dramatic in patients who underwent 
reperfusion  or  early  revascularization  treatment  than  in  those who  did  not  receive  these 
therapies. Thus, in the National Registry of Myocardial Infarction 4 (n=115 273), the mortality 
odds ratio (comparing the highest to the lowest quartile of leukocyte count) was 4.0 for those 
not undergoing reperfusion therapy (n=83 775), and the absolute in-hospital mortalities were 
18.6% and 4.7%, respectively, for the highest and lowest WBC count quartiles, whereas the 
comparable odds ratio for those undergoing reperfusion therapy with thrombolytic agents or 
primary percutaneous coronary intervention (PCI; n=30 954) was 2.7 (9.3% versus 3.5%). 
These data yield absolute differences in mortality between the highest and lowest WBC count 
quartiles of 13.9% for those not receiving reperfusion therapy and 5.8% for those receiving 
such therapy.37
Leukocytes and acute myocardial infarction  :  
The  association  between  leukocytosis  and  increased  morbidity and  mortality  of 
ischemic vascular disease has been observed for more than half a century. Recent studies 
>350,000 patients confirm robustness of the association and dramatically higher relative and 
absolute acute and chronic mortality rates in patients  with high versus low WBC count.43 
Whether elevated white cell count is a marker of the inflammatory process or is direct risk 
factors for acute myocardial infarction remains unclear. 37 An elevated WBC count has been to 
be independent predictor of long term mortality and all cause mortality there have been few 
studies64,65 examining the association WBC count and early death.
 A  study  from  National  Registry  of  Myocardial  Infarction  (NRMI),  evaluated  the 
association  between  WBC  count at  admission  and  in-hospital  mortality  following  AMI  in 
115,273 patients at 1,189 hospitals in the United States. They observed a strong association 
between WBC count and in-hospital  mortality of AMI patients.  After adjustment for patient 
demographics, medical  history,  presenting  clinical  characteristics,  and  treatment factors, 
patients in the higher WBC count quartile remained with significantly increased odds of death. 
This  association was independent  of  age,  gender,  and reperfusion status,  with increasing 
WBC count associated with progressively higher mortality. The unadjusted odds ratio (OR) 
four  versus  the  first  quartile  showed strong associations  with  in-hospital  mortality  among 
entire population was 4.09 (95%CI =3.83 to 4.73) and following adjustment for covariates, the 
magnitude of the odds ratio attenuated, but odds ratio remained significant (OR: 2.71[95%CI= 
2.53 to 2.73]). 37
Epidemiologic studies also have demonstrated correlations between the white blood 
cell count and the risk of acute myocardial infarction and stroke. Early studies have shown 
that patients with elevated white blood cell (WBC) count were at higher risk of mortality and 
recurrent  AMI.  More  recent  studies  have  confirmed the  association  between an elevated 
WBC and clinical outcomes in AMI patients and furthermore suggested that WBC could serve 
as a simple and inexpensive tool for risk stratification in acute coronary syndromes.34 
An  elevated  WBC count  may  be  a  marker  for  chronic  inflammation  secondary  to 
tobacco  smoking  as  well  as  to  other  factors,  and  this  inflammation  could  contribute  to 
ischemic  risk,  Recent  advances  in  the  understanding  of  microvascular  injury,  leukocyte 
activation, and hemorrheology strengthen the hypothesis that WBCs are major contributors to 
microvascular injury and atherogenesis and that chronic leukocytosis reflects ischemic risk in 
a direct rather than an indirect manner. 
Keskin et al  have shown that elevation of WBC count during AMI is associated with 
adverse outcomes. They also found an association between high WBC count and 30-day 
MACE, failed to reach statistical significance (p 0.059). This finding is clinically important and 
encourages the use of this parameter for the risk of  stratification of patients with AMI.45,61 
Understanding of microvascular injury, leukocyte activation, and hemorrheology strengthen 
the hypothesis that WBCs are major contributors to microvascular injury and atherogenesis 
and that chronic leukocytosis reflects ischemic risk in a direct rather than an indirect manner. 
As early as 1954, Cole et al. reported that AMI patients with WBC count higher than 15,000 
cells/mm3 who were admitted to the hospital had a risk of death within 2 months that was four 
times as great as the risk of patients with normal WBC count (<10,000 cells/mm3).46   Maisel et 
al reported that the WBC count on admission to the hospital was an independent predictor of 
early ventricular  fibrillation.  3% of  patients  with  normal  or  modestly elevated  WBC count 
(>15,000 cells/mm3) suffered ventricular fibrillation, while 15% of patients with more elevated 
WBC count experienced ventricular fibrillation.44  Furmanand etal examined the relationship 
between  WBC  and  short-term  prognosis  following  AMI,  and  found  that  patients  in  the 
uppermost quintiles of WBC were more likely to have a complicated hospital course and more 
extensive acute myocardial  necrosis.  
 In-hospital  mortality in  relation with WBC count  in115,273  patients  in the National 
Registry of Myocardial Infarction 4. Showed that a J shape relation of the data with patients 
with high WBC count and very low WBC count constituting a subgroups with higher mortality 
(Figure 8).37
Figure  8. A  J-shaped relationship between mortality and leukocyte count was observed in National 
Registry of Myocardial Infarction 4 study.37
As suggested by Gurm et al, a very low WBC count may indicate general poor health 
and  thus  confer  additional  mortality  risk  independent  of  the coronary  artery  disease.  In 
addition,  he suggested that  inclusion of  such a subgroup in  the analysis  might  dilute  the 
association between the WBC count and cardiovascular risk in the remaining population.36
Barron et al, reported on pooled data on 992 patients from the Thrombolysis in Myocardial 
Infarction (TIMI) 10A and 10B trials of tenecteplase and reteplase treatment of acute 
myocardial infarction. WBC count was obtained at entry, before drug administration. Higher 
WBC counts were associated with resistance to thrombolysis, increased thrombus burden, 
and impaired microvascular perfusion.  30 day mortality was 10.4% in patients with WBC 
count >15 000/mm3 and 0% in patients  with WBC count  was 5000/mm3, and a similar 
difference was noted for the development of congestive heart failure or shock.  Barron et al 
concluded that an elevated leukocyte count was associated with a poorer response43 
 Figure 9. Association between WBC count and development within 30 days of death or either 
congestive heart failure (CHF) or shock in 975 patients in the TIMI 10A and 10B trial.43 
to therapy and not just a larger infarct at presentation. This was true even after adjusting for 
other risk factors like admission TIMI flow, myocardial perfusion grades, anterior myocardial 
infarction location, baseline and maximum creatinine kinase (CK) levels and smoking status. 
Thus, WBC count demonstrated a strong trend toward an independent association with the 
development of new congestive heart failure and death (odds ratio, 1.21; P=0.07) (Figure 9).43
Differential leukocyte count as a risk factor and prognostic indicator  : 
Most studies of the association of leukocytosis and ischemic vascular disease recorded a total WBC 
count without a leukocyte differential analysis, and thus, there are relatively few data on the specific cell type 
most associated with the increased risk. In the CAPRIE study, elevations in neutrophils and to a lesser extent 
monocytes  showed  significant  associations  with the  risk  of  recurrent  ischemic  events,  but  elevations  in 
lymphocyte count showed, if anything, an inverse relationship to the risk of recurrent events.71 In the Evaluation of 
c7E3 for Prevention of Ischemic Complications (EPIC) study, the total WBC count correlated best with 3-year 
mortality,  but  the neutrophil count also showed a correlation.72  The monocyte count  was not correlated with 
outcome, and as in the CAPRIE study, the lymphocyte count demonstrated an inverse relationship. Among the 
leukocytes, morbidity and mortality is most closely associated with the neutrophil count. Monocyte production of 
tissue factor is well established and can be enhanced by activation, providing a direct link to thrombosis; the 
importance of neutrophils as a source of tissue factor is less certain.47   It is notable that an inverse relationship 
between mortality and lymphocyte count was observed, even though the relationship was not as strong as the 
direct associations involving total WBC count and neutrophils.  Because lymphocyte count are depressed by 
elevated glucocorticoid levels, even during the diurnal cycle,48 it is possible that the lower lymphocyte count in 
patients  with  a  poorer  prognosis  reflect  elevated glucocorticoid  levels.  In  fact,  relative  lymphocytopenia  in 
patients  with  chest  pain  was found to  be similar  to  rapid  creatinine kinase-MB in  diagnosing a  myocardial 
infarction  (sensitivities of  58%  and  56%  for  lymphocytopenia  and  elevated  rapid  creatinine kinase-MB, 
respectively; specificities of 91% and 93%); elevated cortisol levels were found in this same group of patients 
(diagnostic  sensitivity  of  68% and specificity  of  86%).  Acanfora  et  al.73 evaluated  the  relationship  between 
lymphocyte count and end points of total mortality and cardiovascular mortality. The three-year mortality rate was 
found to be 64% in persons with a lymphocyte count 20% versus 40% in those with a lymphocyte count of 20% 
(p = 0.0001). The multivariate adjusted hazard ratio of mortality was found to be 1.73 (95% confidence interval 
(CI) 1.21 to 2.48, p = 0.0026).
In the Hiroshima and Nagasaki Adult Health Study49  the total leukocyte count correlated positively with 
the incidence of CAD in a large population of individuals free of disease at baseline. When differential cell count 
were considered, a correlation was found between moderately elevated eosinophil count and increased risk of 
disease, as well as between neutrophil, eosinophil, and monocyte (but not lymphocyte) count and the incidence 
of disease. The Paris Prospective Study II50  revealed that, after adjustment for other variables, the risk of CAD 
increased 1.15 times for each increase of 100cells/mm3 in monocyte count. Prospective studies have shown that 
the inflammatory cell activity and leukocyte count may be useful prognostic indicators in patients with acute MI or 
UA. In a one-year follow-up study of  patients with UA,51  patients who had the highest  leukocyte count were 
roughly eight times more likely to have a major cardiovascular event than patients with the lowest count and 
were five times more likely to have one than all other patients. 
Leukocytes    and other risk factors of CAD :     The associations between leukocyte count and other risk factors 
for CAD, especially smoking, have been evaluated in a number of studies. The leukocyte count has been shown 
to  correlate positively  with  cigarette  smoking,  serum  total  cholesterol, serum  triglycerides,  clotting  factors, 
hematocrit, fasting glucose levels, and diastolic blood pressure and inversely with serum high-density lipoprotein 
cholesterol, forced expiratory volume, forced vital capacity, and height. The interdependence of leukocyte count 
and smoking remains unclear, as the WBC count is usually higher in smokers. However, the WBC count has 
been shown to be an independent predictor of CAD in multivariate analyses adjusting for other risk factors, 
including smoking in different population.52 
The strong association between cigarette smoking and elevated leukocyte count has 
been documented in many studies and even regular exposure to "second hand" smoke is 
associated with  increased  leukocyte  count.54,55 There  is  increasing  evidence  suggesting  a 
relationship between obesity and inflammation. A higher BMI is associated with higher serum 
C-reactive protein (CRP) concentrations in both children and adults suggest a state of low-
grade systemic  inflammation  in  overweight  and  obese  persons.  Kullo  et  al.  showed  that 
persons with a BMI  30 kg/m2 had a higher WBC count than those with a BMI <25 kg/m2 
(WBC count = 5.86 vs. 5.26 x 109/l, respectively; p < 0.05). Huang et al.56 reported a positive 
and significant relationship between the total  WBC, neutrophil,  lymphocyte, and monocyte 
count with smoking and BMI (p < 0.001). 
Two case-control studies in disease-free subjects57,58 confirmed the correlation between 
leukocyte count and CAD. One of these studies,59  which evaluated gender-, age, and risk-
matched subjects, found that the mean leukocyte count was higher in patients than in control 
subjects (8,000/mm3 vs. 7,500/mm3). The other study, which used a cohort of dyslipidemic 
men from the  Helsinki  Heart  Study of  coronary atherosclerosis  primary prevention,  found 
leukocyte count  to be higher in patients than in controls at  baseline before admission. In 
addition, smokers with elevated white blood cell (WBC) count had a higher relative risk for 
disease than non-smokers. As discussed later, the WBC count is usually higher in smokers; 
however,  their  effect is  mostly  additive,  as  WBC is  an  independent  risk  factor  for CAD. 
Retrospective studies in disease-free subjects have also correlated the leukocyte count and 
CAD. A large, retrospective five-year cohort  study  60 showed not only that high leukocyte 
count at baseline correlated with the development of acute coronary syndromes, but also that 
baseline  leukocyte  count  were  higher in  diseased  patients  than  in  patients  who  had  no 
significant CAD.  The most important questions are: 1) Which leukocyte count 
cutoff points will  be most useful for predicting CAD risk in clinical practice? 2) What is the 
relative predictive value of differential leukocyte count? Which leukocyte subtype or subtypes 
(eosinophils, basophils, or neutrophils), if any, will be most useful for predicting risk? 3) Will 
combining  serum  markers  of  inflammation (such  as  CRP,  lipoprotein  phospholipase  A2, 
pregnancy-associated plasma  protein-A,  and  myeloperoxidase)  with  the  leukocyte  count 
increase predictive ability?
SUMMARY: Atherosclerosis is a multifactorial disease with dyslipdemia, hyperglycemia, 
smoking  and  other  causes  of  endothelial  injury  and  genetic  predisposition,  all 
contributing to pathogenesis. In recent years it has been recognized that atherogenesis 
represents  an  active  inflammatory  process  rather  than  simply  passive  injury  with 
infiltration  of  lipids.  The  white  cell  count  has  been  proposed  as  a  biomarker  for 
cardiovascular risk prediction.  Among the inflammatory markers C-reactive protein has 
been extensively studied and clinically applied for risk stratification in CAD. However its 
value as a predictor of  cardiovascular risk been questioned recently. Hence, the need 
to develop and apply additional complementary inflammatory markers of cardiovascular 
risk. The WBC count provides an assessment of inflammatory status. This inexpensive 
and universally obtained test has not been fully explored or exploited for its predictive 
ability.
Materials & Methods
Study population: 
We recruited 118 patients with acute myocardial infarction, admitted in the Department 
of Cardiology, Christian Medical College, Vellore, between August 2004 to June 2006. 
Base line assessment: 
A detailed medical history regarding risk factors like-diabetes mellitus, hypertension, 
smoking, obesity, dyslipidemia and family history of premature coronary artery disease; as 
well  as  previous  symptoms  such  as  preinfarction  angina  were  obtained.   Full  physical 
examination was done in all patients. Killips score in acute MI on hospital admission, BMI, 
total and differential WBC count, serum creatinine  level  were obtained. Serum level of hs 
CRP was measured at admission in all patients. Any evidence of the presence of an obvious 
source of infection, either by clinical assessment or laboratory investigations served as basis 
for exclusion from the study.
Definitions and Data Collection :
Acute ST segment elevation myocardial infarction was defined as typical chest pain 
with ST-segment elevation at J point in >2 contiguous leads, with a cutt off >0.2mV in  V1, V2 
or  V3  or  >0.1mV in  other  leads.  Body mass  index  (BMI)  was  defined  as  the  weight  in 
kilograms  divided  by  the  square  of  the  height  in  meters.  Detailed  in-hospital  data  were 
obtained regarding all adverse events. 
Inclusion  criteria : 
        • All Patients presenting to the hospital with ST elevation myocardial infarction. 
1Exclusion  criteria : 
1    • Patients with other systemic illnesses where CRP is elevated (infections, 
0   chronic Inflammatory diseases like – Rheumatoid arthritis etc.) 
2    • Patients with malignancies 
3    • Patients who had recent surgery / trauma 
Echocardiographic studies :
Echocardiographic  measurements  were  obtained  by  using  the  HP  Sonos  5500 
echocardiography machine on the first  or  second day of  admission.   Left  ventricular end 
diastolic volume, end systolic volume and ejection fraction, were assessed from the apical 
four-chamber  view  using  Simpson's  rule.  Regional  wall  motion  abnormalities  were  also 
documented. 
Laboratory methods of measuring hs-CRP and WBC count : 
hs-CRP was  measured on the Immulite 2000(DPC) by a chemiluminiscent immuno 
assay.   CRP  in  each  serum sample  is  captured  by  a  ligand  labeled  anti  CRP  murine 
monoclonal  antibody.  The  detection  antibody  is  rabbit  polyclonal  anti  CRP  tagged  with 
alkaline phosphatase.  The entire complex is bound by antiligand on a polystyrene bead. 
Alkaline Phosphatase acts on the chemoluminescent substrate producing dioxetone which 
releases  photons  and  is  measured  as  light  units  which  is  directly  proportional  to  the 
concentration of CRP.
    The WBC count was measured using a standard technique and expressed as absolute 
count per mm3. WBC count was analyzed using Beckman Coulter equipment.
Post MI complications
The following variables were taken for the purpose of post MI complications:
1. Post infarction angina
2. Cardiogenic shock
3. Mitral regurgitation
4. Left Ventricular failure (LVF)
5. Complete heart block
 6. Arrhythmias/ LBBB/RBBB/LAHB/LPHB
7. Pericarditis
8. Cardiac rupture
9. Re- infarction 
10. Mortality
11. Non-cardiac complications such as CVA.                                                                        
Statistics :
All  continuous variables were expressed as mean and standard deviation; whereas 
categorical variables were expressed as numbers with percentages. For univariate analysis, 
categorical variables were compared by using chi-square test or Fisher's exact test (where 
the  numbers  were  small).  Multivariate  analysis  was  performed  using  logistic  regression. 
Receiver operator characteristic curves were plotted to obtain best cut off points. Statistical 
significance was defined as a value of p <0.05. All computations were performed using SPSS 
13.0 software, Chicago, Inc.                                                      
Results
Of the 118 patients, 102 were men and 16 were women. The age of these patients was 
56.06 ± 12.12 (range 27-96 years). Hypertension was present in 65 patients, diabetes in 69 
patients. 106 of the 118 patients had thrombolysis (89.9%).       Seven patients underwent 
primary PTCA, all subjects were men; 5 (4.9%) patients were not thrombolysed because of 
late presentation and advanced age.  Eleven patients underwent rescue PTCA (10 male & 1 
female) (Table 1). Out of those who underwent cardiac catheterization, 5 (29.4%) patients 
had single vessel disease, 9 (52.9%) had double vessel disease and 3 (17.6%) had triple 
vessel disease. 83 patients (69.2%) had LVEF <50% and 37 (30.8%) had LVEF ≥50%. 
Table 1. Baseline clinical characteristics
We measured hs-CRP level and white cell count on the date of admission.  The hs 
CRP was 5.35 ± 6.5mg/dL, the CKMB was 71.7 ± 77.1 IU/L, serum creatinine was 1.13 ± 
0.3mg%, and the WBC count was 13309.32 ± 3708count /mm3. Differential count results are 
as follows neutrophils 72.42 ± 12.3%, lymphocytes 20 ± 9.9%, monocytes 4.42 ± 2.82%, 
basophils 0.25 ± 0.45%, and eosinophils 1.48 ± 1.8% (Table 2).
The average hospital  stay was 4.5 ± 2.0 days.  Six patients  developed cardiogenic 
shock, one recovered, five patients expired. In total eleven patients expired during hospital 
course; eight patients expired within 48 hours of admission. Sixty-nine (58.5%) patients were 
discharged uneventfully.  Details of post MI complications are listed in table 3 and figure 1.
Table 3. Frequency And Percentage Of Occurrence Of 
The Various Post MI Complications
Post MI complications Frequency Percentage
Mitral regurgitation 5 4.2
Complete heart block 6 5.1
Cardiac rupture 1 0.8
Cardiogenic shock +recovered 1 0.8
Arrhythmia /LBBB/RBBB 5 4.2
Table 2. Baseline Laboratory Findings
Variables
CKMB (IU/L) 71.7 ± 77.1
hs-CRP ( mg/dL) 5.35  ± 6.5
WBC count (cells/ mm3) 13309 ± 3708.6
Neutrophils% 72.4 ± 12.3
Lymphocyte % 20 ± 9.9
Monocyte % 4.42 ± 2.82
Basophil % 0.25 ± 0.45
Eosinophil % 1.48 ± 1.8
Post MI angina +  reinfarction 10 8.5
Pericarditis 2 1.7
Left ventricular failure + reinfarction 7 5.9
LV  thrombus 2 1.7
Cardiogenic shock +death 5 4.2
Arrythmia(VT+VF)+death 2 2.5
Non cardiac complication 2 1.7
The presence of any complication after the acute myocardial infarction was taken as 
the  outcome.  Complications  occurred  overall  in  41.5%  of  patients.  The  most  common 
complication was post infarction angina, which preceded most of other complications. In total 
11(9.3%) patients  expired during hospital  course;  eight  patient  expired  within  48  hours of 
admission. Most common cause of death was cardiogenic shock (Table 3 and Figure 1).
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Figure 1: Bar diagram showing Post MI complications 
(Table 4). There were 70 patients with anterior wall MI and 48 patients with non-anterior wall 
MI (including inferior, posterior and right ventricle MI) respectively. Predominantly anterior wall 
MI patients (n=33, 71.7%) had more post MI complications compared to non AWMI (n=13, 
28.3%)( p =0.028, as analyzed by chi square test) (Table 4).
Table 4. Post MI Complications Analyzed By the Site of Myocardial 
Infarction
We looked at the presence of an association between the various baseline  risk factors and 
the occurrence of post MI complications.  The window period of presentation, killips class at 
admission, LV dysfunction, hs-CRP level, total WBC 
Table 5. Univariate Analysis Assessing Post MI Complications 
By Baseline Features And Various Risk Factors*
Without Post MI 
complications
With Post MI 
complications
p 
Value
Window period(hrs)
<  3
3 - 6
> 6
12(75)
44(66.7)
16(44.4)
4(25)
22((33.3)
20(55.6)
0.042
Killip  class
I
II
III
IV
44(80)
26(55)
2(15.4)
0(0)
11(20)
21(44.8)
11(84.6)
3 (100)
0.001
AWMI
Non AWMI
37(51.4}
35(48.6)
33(71.7}
13(28.3)
0.028
Anterior wall MI
n =70
Non-anterior wall MI
n  =48 P Value
Post MI 
complications 
n(%) 33(77.7) 13(28.3) 0.028
LVEF%
< 50
> 50
48(56.2)
30(83.3)
40(48.8)
6(16.7)
0.001
CKMB IU/L
<25
> 25
26(68.4%)
46(57.5%)
12(31.6)
34(42.5) 0.25
HsCRP mg%
< 3
> 3
50
23
12
35
<0.001
LDL mg%
< 100
> 100
27(62)
44(64)
16(37)
24(35)
0.838
hsCRPmg%+LDL mg%
<3 + <100
≥ 3 + <100
< 3 + ≥ 100
≥ 3 + ≥100
22(73}
6(35.3)
26(86.7)
18(61)
8(26.7)
11(64.7)
4(13.1)
23(56)
<0.001
*Values given as n. (%).
count,  and neutrophil  & lymphocyte percentage in the differential  count were found to be 
significant  in  univariate  analysis.  LDL level  by itself  did  not  have a significant  correlation 
(Table 5, 6, 7 & 8). 
Table 6. Association Between hs-CRP And Post MI Complications 
hs-CRP mg/dL Post MI complications (n) p Value
<3 12
≥3 34
0.001
We analyzed post infarction complications in relation to quartiles of hs-CRP level (Figure.7)
Table 7. Post MI Complications During Hospital Course 
By Quartiles Of hs-CRP Levels
We looked at post MI complications stratified by total and differential WBC count as 
shown  in  table  8.  As  seen,  there  is  a  significant  association  between  the  post  MI 
Post MI complications Quartiles of hs- CRP (mg %)
<1.13 1.13 - 2.7 >2.7 - 7.2 >7.2
Mitral regurgitation 2 1 2 0
Complete heart block 2 0 4 0
Cardiac rupture 0 0 0 1
Cardiogenic shock +recovered 1 0 0 0
Arrhythmia /LBBB/RBBB 1 0 2 2
Post MI angina ± reinfarction 1 1 2 8
Pericarditis 0 0 1 1
LVF ± reinfarction 0 2 0 5
LV thrombus 1 0 1 0
Cardiogenic shock + reinfarction 
+death
1 0 1 3
Arrythmia(VT+VF)+death 0 0 2 1
Non cardiac complication 1 1 0 0
* Values given as n
complications and total WBC count, as well as neutrophil and lymphocyte count. 
Table 8. Univariate Analysis Assessing Post MI Complications                                  By 
WBC And   Differential Count *
With Post MI 
complications
Without  Post MI 
complications
p Value
WBC count/mm 3
5001to10000
>10001 to15000
> 15000
16 (72)
43 (69.4)
13 (38.2)
6 (27.3)
19 (30.6)
21 (61.8)
0.005
Neutrophil  Bandforms 24 (54.3) 20 (45.5) 0.266
Neutrophil %
<65
66-75
>75
25 (80.6)
27 (65.9)
20 (43.5)
6 (19.4)
14 (34.1)
26 (56.5)
0.003
Lymphocyte %
<14
14-20
21-24
>24
16 (43.3)
17 (63)
16 (61.5)
23 (82.1)
21 (56.8)
10 (37)
10 (38.5)
5  (17.9)
0.017
                                               
  *Values given as n. (%).
We also analyzed post infarction complications in relation to white cell count in various groups 
(Table 9). 
Table  9.  Post MI Complications In Relation To Leukocyte Count
Post MI complications
WBC count/mm3
5000 to 10000 10000 to 
15000
>15000
Mitral regurgitation 0 4 1
Complete heart block 2 1 3
Cardiac rupture 0 1 3
Cardiogenic shock + recovered 0 0 1
Arrhythmia /LBBB/RBBB 0 3 2
Post MI angina  ±  reinfarction 1 4 5
Pericarditis 0 2 0
Left ventricular failure ± 
reinfarction
1 1 5
LV  thrombus 1 0 1
Cardiogenic shock + death 1 2 2
Arrhythmia(VT+ VF ) + death 0 2 1
Non cardiac complication 2 0 0
                            *Values given as n.              
The presence of any association between various traditional risk factors and CRP level was 
determined by Chi Square and Fisher's exact tests where applicable. The factors that were 
significantly associated with hs-CRP level more than 3 mg/dl were   window period in hours 
and post MI complications (Table 10).
Table  10. Relationship Between Risk Factors And hs-CRP Level*
hs-CRP<3mg/dl 
n=61
hs-CRP>3mg/dl
n=57 P Value
Male/female 54/7(52.5/43.8) 48/9(97.1/56.3) 0.49
Age <55/>55yrs 31/30(52.5/50.8) 28/29(47.5/49.2) 0.72
HTN 35 (53.9) 30 (43.5) 0.60
DM 39 (53) 3043.5) 0.22
Dyslipidemia 25(41) 47 0.09
Smoker 31 28 0.85
BMI >25kg/m2 36 (59) 48(75.9) 0.05
Window period (hrs) 
in 3 category 
<3/>6
3to6/>6
<3/ 3-6
14(23)
34(55)
13(21.3)
2(3.5)
32(56)
23(40.4)
0.003
  Killips  Class I
II
III
IV
33(54)
23(37.7)
5(8.2)
0(0)
22(38.6)
24(48)
8(14)
3(5.3)
0.123
AWMI 34(55.7) 36(63.2%) 0.412
TC >200mg% 16(26.7) 15(28%) 0.79
LDL 100mg% 29(49.2) 14(26.9) 0.016
HDL<40 mg% 39(65) 25(48) 0.07
TGL    >150mg% 34(55.7) 27((51) 0.06
Post MI 
complications 12(19.7) 34(59.6) 0.0001
                * Values given as n. (%).
In univariate analysis, LVEF <50% was significantly associated with a high level of 
hs-CRP (Table 11).
Table 11. Univariate Analysis Of Echocardiographic 
         Parameters With hs-CRP
                
     
  
We also analyzed the LV systolic function in relation to hs-CRP and WBC count.  Table 12 
shows  the  significant  inverse  correlation  between  hs-CRP  level  and  WBC  count  with 
occurrence of LV dysfunction.
Table 12.Univariate Analysis of LV EF with hs-CRP and WBC
LV EF 
<50%
LV EF 
>50%
P Value
hs-CRP mg%
< 3
>3
35(42.7)
22(72.2)
47(57.3)
10(27)
0.003
WBC Count /mm3
<10000
10000 -15000
>15000
10(12.2)
45(54.9)
27(32.9)
12(33.3)
17(47.2)
7(7(17.4)
0.002
hs-CRPmg% + WBC/mm3
<3    + <10000
<3    + >10000
>3    + <10000
>3    + >10000
3(3.7)
28(34.1)
17(20.7)
34(41.5)
9(25%)
16(44.48%)
5(13.3%)
6(16.7%}
<0.001
(Fisher's exact test)
hs-CRP mg% + LDL mg%
<3   + <100
>3   + <100
<3    + > 100
>3    +   >100
20(66.7}
12(70.6)
13(43.3)
37(90.2)
0(33.3)
5(29.4)
17(56.7)
4(9.8)
<0.001
(Fisher's exact test)
LDL mg%
<100
>100
27(36)
48(69)
18(44)
20(55)
0.28
                         *Values given as n. (%).
We looked at the presence of an association between the various risk factors and the 
occurrence of any post MI complications.  Gender, total WBC count (stratified as  5000 to 
10000; 10000 to 15000; >15000 cells/mm3),  hs-CRP level  (<3mg% &≥3mg%) and LV EF 
(<50%& ≥ 50%) had a significant association by multivariate analysis (Table 5).  Traditional 
risk factors such as diabetes, hypertension and smoking were not of significance in predicting 
occurrence of post MI complications.  Multivariate analysis using logistic regression was done 
to analyze the significance of various risk factors in the occurrence of post MI complication. 
The following table shows the odds ratio (OR) and 95% confidence intervals(CI). The odds 
ratio of a hs-CRP level of ≥ 3 mg/dl for post MI complications was 5.2 (95% CI: 2.0 to 13.7) 
and odds ratio of a white cell count of >15000 cells/mm3 for post MI complications was 2.7 
(95%CI: 1.2 to 5.7) (Table 13)
Table 13. Logistic Regression Analyzing Post MI 
Complications By Various Risk Factors
ROC curves  were  plotted  with  hs-CRP,  total  WBC count,  absolute  neutrophil  and 
lymphocyte count against presence or absence of post MI complications in order to determine 
the relationship of these risk factors with the outcome measure and find out best cut off points 
which predict the occurrence of complications with optimal sensitivity and specificity (Figure 2, 
3 & Table 13).
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Figure 2. ROC Curve Plotted with hs-CRP, total WBC count and absolute 
neutrophil count against Post MI complications
Table 14. Best Cut Off Points Obtained From The ROC Curves To Predict Occurrence 
Of Post MI Complications
Variable Cut off point Sensitivity% Specificity%
hs-CRP mg% 2.9 65.3 71.7
WBC Count/mm3 12,950 73.5 63.9
Neutrophil count/mm3 9,720 65.2 69.4
  
       For the lymphocyte count, it was observed that a lower lymphocyte count, to predict 
Diagonal segments are produced by ties.
1.00.80.60.40.20.0
1 - Specificity
1.0
0.8
0.6
0.4
0.2
0.0
 Sensitivity 
Source of the Curve
Absolute neutrophil Count
WBC count / cumn
hs C-reactive protein (mg%)
Reference Line
Source of the Curve
count
Absolute 
neutrophil
WBC count 
/cumm
protein  in mg
%
serum hs C-reactive
Reference Line
greater occurrence of post MI complications, i.e., the relationship was inverse. Hence a curve-
taking non-occurrence of complications as the outcome was plotted (Figure 3).
       By the ROC curve, the cut off point for the absolute lymphocyte count below which post 
MI complications would be predicted to be 1530 cells/mm3 with a sensitivity of 91.7% and 
specificity of 43% (Figure 3).
Figure 3. ROC Curve Plotted With Absolute Lymphocyte Count Taking Against Non 
occurrence of Post MI Complications as outcome
We analyzed  parameters  of  ventricular  systolic  performance  namely LVEF (%)  and 
LVEDV (ml)  in  relation  to  hs-CRP.  As  the  scatter  plots  demonstrate,  a  significant  linear 
correlation exists between hs-CRP and these parameters. Figure 4 shows that hs-CRP levels 
correlate positively with LV end diastolic volume.
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The next scatter plot demonstrates that hs-CRP level correlates inversely with left ventricular 
ejection fraction (LVEF) (Figure 5). 
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Figure 4. Scatter Plot Showing The Association Between hs-CRP And LV End 
Diastolic Volume
Figure 5. Scatter Plot Showing A Correlation Between hs-CRP And LV Ejection 
Fraction (LV EF%)
Discussion
Our study shows a significant association between hs-CRP levels and total WBC count 
at admission to the in-hospital complications observed in STEMI patients.
Of the total 118 patients, complications occurred in 42% of the patients; 11 deaths (9.3%) 
occurred in the hospital course. The most common post MI complication was post 
infarction angina and most common cause of mortality was cardiogenic shock.
In  our  study,  a  high  hs-CRP  level  (  ≥ 3  mg/dL  ),  was  shown  to  be  significantly 
associated with post MI complications during hospital course, such as post infarction angina, 
mitral regurgitation, complete heart block, left ventricular failure and mortality etc., odds ratio 
was 5.2 (95% CI:2.0-13.7; p<0.001). Our results are in agreement with O Keskins et al 61 and 
partially with Suleiman et al  62 who collected blood samples at the time of admission, within 
6-12 hrs and 12-24 hrs respectively. O Keskins et al 61 reported that high hs-CRP (>2.0mg%), 
collected once at admission was an independent predictor of 30 day recurrent cardiac events, 
such as  reinfarction,  post  MI  angina  and  cardiac  death,  the  odds  ratio  was  1.024  (95% 
CI:1.002–1.047;P <0.03).  Suleiman  et  al  16 reported  that  a  high  CRP level  (>2.23mg%) 
obtained within  12-24 hours  of  symptom onset,  was an independent  predictor  of  30 day 
mortality  and  heart  failure,  relative  risk  was  3.0  (95%  CI:1.3-7.2),  but  not  associated 
significantly with the development of post infarction angina or recurrent myocardial infarction 
in patients with acute myocardial infarction. Zebrack et al 63 reported that CRP level, collected 
in acute myocardial infarction patients at predischarge was not associated with the death or 
recurrent cardiac events (Table15). 
The importance of an elevated leukocyte count in the setting of acute coronary events has 
been described from very early times. A high WBC count has been shown to increase the risk 
of developing MI and increased post MI adverse events.74 
Table 16.  White Cell Count And Relative Risk / Odds Ratios 
Table 15. hs-CRP level and odds ratios for post MI complications
Study hs-CRP level RR/OR 95% CI
OKeskins et al 61
>2.0 mg% (once at 
admission within 
6-12 hrs )
1.024 for 
recurrent cardiac 
events within 30 
days
1.002 to 1.047
Suleiman et al 62
>2.23 mg% (once 
at admission) 
within 12 -24hrs
3.0 for 30 d mortality 
and heart failure
1.3 to 7.2
Anzai et al 35
>20 mg%
(peak )
4.72 for cardiac 
rupture & one year 
cardiac death
1.6 to 13.6
Zebracks et al  63
CRP levels, at 
predischarge
Not associated with 
death or recurrent 
cardiac events
Helsinki Heart Study Highest quartile 
3.56; for risk of MI 
or death
1.93 to 6.3
Our study
≥ 3 mg% (once 
at admission) 
within 6 to 
12hrs
5.2 for post MI 
complications during 
hospital course
2.2 to 13.7
For Post MI Complications
Epidemiologic studies have demonstrated correlations between the WBC count and 
the risk of acute myocardial infarction and stroke.  The risk of AMI or death is approximately 
four times greater in persons with WBC count high in the normal range (>9,000 cells/mm3) 
than in persons with WBC count low in the normal range (<6,000 cells/mm3). A high WBC 
count also predicts a greater risk of re-infarction and of in-hospital death. Cole et al 46 reported 
Study WBC count / mm3 RR/OR 95% CI
Furmans et al 64 Uppermost quintile 1.7     1.14 to 2.58
OKeskins et al 61
>14000 at admission 
within 6-12hrs
1.013 0.9 to 1.0
Barron et al 38
(TIMI) 10A and 10B 
trials
>15000 within 24 hrs 10.2% 30 days mortality
Cole et al 35 >15000
32% of with MI died within 
2 months
NRMI 37
Fourth versus first 
quartile
2.71 2.53 to 2.9
Our study
>12900 at admission 
within 6 hrs
2.7 1.2 to 5.7
that the risk of death within 2 months in patients with acute myocardial infarction was four 
times greater in those with WBC count higher (> 15,000 cells/mm3) than those with normal 
WBC count (<10,000 cells/mm3).   Furmans et al  64 examined the relationship between WBC 
and short-term prognosis following AMI, and found that patients in the uppermost quintiles of 
WBC were  more  likely  to  have  a  complicated  hospital  course  and  more extensive  acute 
myocardial  necrosis.  The  adjusted  odds  ratio  (OR)  four  versus  the  first  WBC quartile  in 
National registry in myocardial infarction was remained significant with in-hospital mortality 
among entire population (OR: 2.71[95%CI: 2.53 to 2.73]). 37
 In the study by Barron et al, 38 he found that WBC count within 24 h of admission for 
an AMI is a strong and independent predictor of in-hospital and 30-day mortality as well as in-
hospital  clinical  events.  Some studies have not  found correlation between high leukocyte 
count and complications following acute coronary syndromes. O Keskins et  al  61  found that 
WBC count was not an independent prognostic predictor for post MI complications, however 
they reported a strong correlation between WBC count, post MI complications and between 
WBC count and CRP levels overall (Table 16).
Our study has shown that a high WBC count was significantly associated with post MI 
complications even after adjustment for other potential confounding factors such as   age, 
diabetes, hypertension, smoking and hs-CRP level.  It was found to be a strong independent 
predictor of post MI complications such as post infarction angina, LV dysfunction.  We also 
analyzed outcome by differential  leukocyte count,  which has been a potential  limitation in 
previous epidemiologic studies.  38,  46,61,64,65 In our study, high neutrophil and low lymphocyte 
percentages were found to be significantly correlated with post MI complications.
We also looked at the best cut off points for hs-CRP level, total WBC count, absolute 
neutrophil (ANC) and lymphocyte count (ALC) in the prediction of post MI complications, by 
plotting the receiver operator characteristic curve. The best cut off point of CRP was found to 
be 2.9 mg/dL with a sensitivity of 71.7% and specificity of 65.3%. The cut off for total WBC, 
ANC and ALC were 12,950  cells/mm3, 9720  cells/mm3  and l530  cells/mm3 respectively with 
sensitivities of 73.5%, 65.2%, 91.7% and specificities of 63.9%, 69.4% and 43% respectively. 
As there is considerable interest in developing hs-CRP as a prognostic tool in the setting of 
acute MI, these cut off values could be useful in risk stratification. These correlations possibly 
reflect  that  coronary inflammation  is  an  ongoing  process during  AMI.  Thus,  inflammatory 
markers, such as CRP level,  WBC count and its differential count can be used to predict 
short-term prognosis in patients with AMI. 
Conclusions
1. In  patients  presenting  with  acute  ST  segment  elevation  myocardial 
infarction, elevated hs-CRP level was associated with significant   
      in- hospital complications (odds ratio = 5.2 [95% CI:2.0-13.7] ).
2. The neutrophil and lymphocyte counts individually were also found to have a 
significant correlation with post MI complications.  By the ROC curve, the 
ideal cut off point for total WBC count to predict post MI adverse events was 
found  to  be  12,950  cells/mm3  with  sensitivity  of  73.5% and  specificity  of 
63.9%. The best cut off point for the absolute neutrophil count to predict post 
MI  complications  was  9,720  cells/mm3 with  sensitivity  of    65.2%  and 
specificity   of 69.4%. 
3. Our  results  suggest  that  hs-CRP  level  and  white  cell  count  obtained  at 
admission in acute ST segment elevation myocardial infarction can be used 
as a marker for identification of patients who are likely to develop significant 
complications in the hospital course.
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Abbreviations & Acronyms
CAD - Coronary artery disease
HTN - Hypertension 
DM - Diabetes mellitus 
BMI - Body mass index 
STEMI  - ST-segment elevation myocardial infarction 
 AMI - Acute myocardial infarction 
LV EF - Ejection fraction of left ventricle 
LDL - Low-density lipoprotein 
HDL - High-density lipoprotein
hs CRP  - High sensitivity C- reactive protein 
LVEDV - Left ventricle end diastolic volume 
WBC - White blood cell count
ALC - Absolute lymphocyte count 
ANC - Absolute neutrophils count
APPENDIX 
STUDY  PROFORMA  
HIGH-SENSITIVITY C-REACTIVE PROTEIN, LEUKOCYTE AND DIFFERENTIAL COUNT 
IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Name    : Age:  Sex: M/F
Hospital No. :
Address :
Height :……….cm Weight :………Kg
Presenting complaint :
Chest Pain  /  Dyspnea   /   Syncope   
Exclusion criteria :
Fever /   connective tissue disorder          
Risk Factor : 
Hypertension : Yes   /   No
Diabetes Mellitus : Yes   /   No
Dyslipidemia : Yes   /   No
Smoking : Yes   /   No
Serum cholesterol (mg%)
TC: TG: LDL: HDL:
Admission Killips  class :  I  /  II  /  III  /  IV
Type of acute myocardial infarction  :
Thrombolysis with streptokinase :   Yes    /   No
Primary PTCA :   Yes    /   No
Rescue PTCA  :   Yes    /   No
Hospital course and post MI complications :  Post infarction angina  /  LVF  /  
reinfarction  /  Pericarditis/ MR  /  VSD  /  Cardiac rupture   /  Cardiogenic shock
 Death :  Yes   /  No         Cause of Death : 
ECHO :   EDV(ml) :             EF :        %
CKMB(IU/L) :    
hs-CRP level (mg%) : 
Total WBC count (cells/mm3): 
Neutrophils%: Lymphocytes%: Basophils%: 
Monocytes%: Esinophils%:

